These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1146 related items for PubMed ID: 20564642

  • 1. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 2. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.
    Biol Blood Marrow Transplant; 2010 Jan 01; 16(1):70-7. PubMed ID: 19733251
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 4. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG.
    Br J Haematol; 2010 Feb 10; 148(4):562-8. PubMed ID: 19919652
    [Abstract] [Full Text] [Related]

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 10; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 6. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
    Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J.
    J Clin Oncol; 2007 Oct 01; 25(28):4452-8. PubMed ID: 17785704
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
    Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H.
    Haematologica; 2006 Nov 01; 91(11):1498-505. PubMed ID: 17043025
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B.
    Clin Lymphoma Myeloma; 2006 Nov 01; 7(3):210-6. PubMed ID: 17229337
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.
    Haematologica; 2005 Dec 01; 90(12):1650-4. PubMed ID: 16330438
    [Abstract] [Full Text] [Related]

  • 11. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    Ann Hematol; 2012 Feb 01; 91(2):249-56. PubMed ID: 21789621
    [Abstract] [Full Text] [Related]

  • 12. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    Lee JH, Lee JH, Kim DY, Kim SD, Choi Y, Kang YA, Seol M, Lee KH.
    Eur J Haematol; 2012 Jun 01; 88(6):478-84. PubMed ID: 22364526
    [Abstract] [Full Text] [Related]

  • 13. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.
    Biol Blood Marrow Transplant; 2012 Mar 01; 18(3):486-92. PubMed ID: 22198542
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
    Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ, Korean Multiple Myeloma Working Party (KMMWP).
    Ann Hematol; 2010 May 01; 89(5):475-82. PubMed ID: 19921192
    [Abstract] [Full Text] [Related]

  • 16. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, Califano C, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A, Brioli A, Tosi P, Baccarani M.
    J Clin Oncol; 2009 Oct 20; 27(30):5001-7. PubMed ID: 19720903
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
    Guo H, Zhou X, Jiang Y, Yang G, Sun C, Zhuang Y, Sun H, Lu M, Qian X, Chen F, Mao J, Chen H, Xia J, Shen Y.
    Am J Hematol; 2010 Jul 20; 85(7):499-501. PubMed ID: 20575036
    [Abstract] [Full Text] [Related]

  • 18. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
    Chang WJ, Kang ES, Lee ST, Kim SH, Kim DW, Kim SJ, Kim K.
    Acta Haematol; 2014 Jul 20; 132(2):226-32. PubMed ID: 24732093
    [Abstract] [Full Text] [Related]

  • 19. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
    Wang YF, Deng SH, Wu T, Xu Y, Zou DH, Wang Y, Zhao YZ, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun 20; 29(6):397-400. PubMed ID: 19031743
    [Abstract] [Full Text] [Related]

  • 20. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
    Clin Transplant; 2009 Jun 20; 23(6):839-47. PubMed ID: 20447186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.